Wednesday, June 10, 2026

Patent intelligence · WO

WO 2024223388

COMPLEXES CRISTALLINS ENTRE LA VELAGLIFLOZINE ET DES AGENTS DE FORMATION DE CO-CRISTAUX SÉLECTIONNÉS, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR …

granted A61K 31/ 351 A IA61K/31351A61P 3/ 10 A IA61P/310
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 18
Applicant portfolio 21
Patent details — WO 2024223388
Jurisdiction
WO
Status
granted
Grant date
Oct 31, 2024
Expiration
Oct 26, 2044
CPC classes
A61K 31/ 351 A I, A61K/31351, A61P 3/ 10 A I, A61P/310
View on Google Patents ↗

Quick answer

WO 2024223388 (COMPLEXES CRISTALLINS ENTRE LA VELAGLIFLOZINE ET DES AGENTS DE FORMATION DE CO-CRISTAUX SÉLECTIONNÉS, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION POUR LA PRÉPARATION DE MÉDICAMENTS) is held by BOEHRINGER INGELHEIM VETMEDICA GMBH [DE]. Status: granted. Granted Oct 31, 2024. Expires Oct 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
CPC classes
A61K 31/ 351 A I, A61K/31351, A61P 3/ 10 A I, A61P/310

More from BOEHRINGER INGELHEIM VETMEDICA GMBH [DE]

Related pharmaceutical patents in our USPTO index.

  1. MX 2025012909

    METHOD FOR INDUCING AN IMMUNE RESPONSE

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Expires Nov 26, 2045

    granted
  2. WO 2025210141

    SYSTÈME D'ADMINISTRATION UTILE POUR L'ADMINISTRATION TOPIQUE D'ARN

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Expires Oct 4, 2045

    granted
  3. US 2025281584

    ACTIVE VACCINATION FOR THE TREATMENT OF NGF-RELATED DISORDERS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Expires Sep 6, 2045

    granted
  4. AR 132581

    COMPOSICIÓN INMUNÓGENA ÚTIL PARA LA AUTOADMINISTRACIÓN POR CERDOS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Expires Jul 11, 2045

    granted
  5. US 2025195525

    ANGIOTENSIN II RECEPTOR ANTAGONIST FOR THE PREVENTION OF SYSTEMIC DISEASES IN CATS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Expires Jun 14, 2045

    granted
  6. WO 2025046413

    VECTEURS DE VIA DE VMN ET LEURS UTILISATIONS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Expires Mar 1, 2045

    granted
  7. WO 2025046414

    VECTEURS DE CDV VIA ET LEURS UTILISATIONS

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Expires Mar 1, 2045

    granted
  8. US 2025064917

    HVT AIV VECTORS AND USES THEREOF

    BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] · Expires Feb 22, 2045

    granted

Frequently asked questions

What is US patent 2024223388?

WO 2024223388 (COMPLEXES CRISTALLINS ENTRE LA VELAGLIFLOZINE ET DES AGENTS DE FORMATION DE CO-CRISTAUX SÉLECTIONNÉS, LEURS PROCÉDÉS DE PRÉPARATION ET LEUR UTILISATION POUR LA PRÉPARATION DE MÉDICAMENTS) is held by BOEHRINGER INGELHEIM VETMEDICA GMBH [DE]. Status: granted. Granted Oct 31, 2024. Expires Oct 26, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.

Who owns WO 2024223388?

BOEHRINGER INGELHEIM VETMEDICA GMBH [DE] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.

When does WO 2024223388 expire?

Our index shows an expiration date of Oct 26, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.